NCT01294293: TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer |
|
|
| Completed | 1 | 20 | US | TLR8 Agonist VTX-2337, Toll-like Receptor 8 Agonist VTX-2337, VTX-2337, Diagnostic Laboratory Biomarker Analysis, Pharmacological Study, pharmacological studies, Pegylated Liposomal Doxorubicin Hydrochloride, doxorubicin HCl liposome, TLC D-99, Paclitaxel, Anzatax, TAX | Gynecologic Oncology Group, National Cancer Institute (NCI) | Malignant Ovarian Mixed Epithelial Tumor, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Undifferentiated Ovarian Carcinoma | 07/14 | | | |